Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts | Zendy

Hideyuki Ikematsu | Zendy; Frederick G. Hayden | Zendy; Keiko Kawaguchi | Zendy; Masahiro Kinoshita | Zendy; M.C.M. de Jong | Zendy; Nelson Lee | Zendy; Satoru Takashima | Zendy; Takeshi Noshi | Zendy; Kenji J. Tsuchiya | Zendy; Takeki Uehara | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts

Author(s) -

Hideyuki Ikematsu,

Frederick G. Hayden,

Keiko Kawaguchi,

Masahiro Kinoshita,

M.C.M. de Jong,

Nelson Lee,

Satoru Takashima,

Takeshi Noshi,

Kenji J. Tsuchiya,

Takeki Uehara

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1915341

Subject(s) - medicine , endonuclease , virology , clinical efficacy , intensive care medicine , biology , dna , genetics

Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research